The drawback in the new immunotherapies in multiple sclerosis (MS) include severe infections that can be fatal.
Treatment with natalizumab, which reduces the immune surveillance of the brain, can lead to the development of progressive multifocal leukoencephalopathy (PML), a typically fatal form of viral encephalitis.